Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Rani Therapeutics Holdings Inc’s stock clocked out at $1.35, down -2.17% from its previous closing price of $1.38. In other words, the price has decreased by -$2.17 from its previous closing price. On the day, 1.34 million shares were traded. RANI stock price reached its highest trading level at $1.42 during the session, while it also had its lowest trading level at $1.35.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on August 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On June 14, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $15.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $10.Rodman & Renshaw initiated its Buy rating on June 13, 2024, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 23 ’25 when IMRAN MIR A bought 2,083,334 shares for $0.60 per share. The transaction valued at 1,260,417 led to the insider holds 2,083,334 shares of the business.
South Cone Investments Limited sold 4,000,000 shares of RANI for $11,074,000 on Oct 21 ’25. The 10% Owner now owns 2,379,194 shares after completing the transaction at $2.77 per share. On Oct 20 ’25, another insider, South Cone Investments Limited, who serves as the 10% Owner of the company, sold 1,923,000 shares for $2.41 each. As a result, the insider received 4,637,314 and left with 6,379,194 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RANI now has a Market Capitalization of 165571472 and an Enterprise Value of 140977648. For the stock, the TTM Price-to-Sale (P/S) ratio is 136.71. Its current Enterprise Value per Revenue stands at 117.481 whereas that against EBITDA is -3.521.
Stock Price History:
The Beta on a monthly basis for RANI is 0.42, which has changed by -0.05479455 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, RANI has reached a high of $3.87, while it has fallen to a 52-week low of $0.39. The 50-Day Moving Average of the stock is -23.03%, while the 200-Day Moving Average is calculated to be 38.46%.
Shares Statistics:
It appears that RANI traded 18.65M shares on average per day over the past three months and 2630590 shares per day over the past ten days. A total of 97.55M shares are outstanding, with a floating share count of 79.32M. Insiders hold about 18.69% of the company’s shares, while institutions hold 12.13% stake in the company. Shares short for RANI as of 1765756800 were 12827731 with a Short Ratio of 0.69, compared to 1763078400 on 8312590. Therefore, it implies a Short% of Shares Outstanding of 12827731 and a Short% of Float of 13.56.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate. The current performance of Rani Therapeutics Holdings Inc (RANI) in the stock market.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.35 and -$0.58 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.32, with 3.0 analysts recommending between -$0.18 and -$0.59.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for RANI’s current fiscal year. The highest revenue estimate was $10.17M, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $5.19M. In the same quarter a year ago, actual revenue was $1.03M
